33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

P.A. Ascierto, H. Tang, S. Dolfi, M.S. Nyakas,I-M. Svane,E. Muñoz Couselo, J.J. Grob, C.A. Gomez-Roca,V. Chiarion Sileni, K. Peltola, J. Larkin, I. Melero, M. Callahan, R. Dummer, P. Djidel, D. Warad, E.J. Lipson, C. Garnett-Benson

Immuno-Oncology and Technology（2023）

引用 0|浏览0